HDM-2020

N/A

Report date: 2026/04/28 20:00:22

Base Information

Drug NameHDM-2020
Drug Alias Namean antibody-drug conjugate composed of a humanized monoclonal antibody PM-012C against fibroblast growth factor receptor 2b (FGFR2b) conjugated to exatecan (topoisomerase I inhibitor) through a cleavable linker Pym-PEG8-Val-Ala-PABHDM-2020
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-Fibroblast Growth Factor Receptor 2bDNA topoisomerase I inhibitors
TargetsFibroblast Growth Factor Receptor 2bDNA topoisomerase I
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHangzhou Zhongmei Huadong Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A